LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lab-On-A-Chip Designed to Minimize Preterm Births

By LabMedica International staff writers
Posted on 25 Apr 2017
Image: Scientists loading the integrated electrokinetically driven microfluidic device with pH-mediated solid-phase extraction coupled to microchip electrophoresis for preterm birth biomarkers (Photo courtesy of Nate Edwards, Brigham Young University).
Image: Scientists loading the integrated electrokinetically driven microfluidic device with pH-mediated solid-phase extraction coupled to microchip electrophoresis for preterm birth biomarkers (Photo courtesy of Nate Edwards, Brigham Young University).
In the USA, a half million babies are born preterm; worldwide, the number is an estimated 15 million and complications associated with preterm birth are the number one cause of death for children under five, and those who live often face a range of health problems.

There presently are no known current biomarker-based diagnostics for preterm births, and doctors typically only pay attention to women who have other clear risk factors. However with the help from a palm-sized plastic rectangle doctors are hoping to minimize the problem of premature deliveries. The chip is designed to predict, with up to 90% accuracy, a woman's risk for a future preterm birth.

Scientists at Brigham Young University have developed a microfluidic device that uses pH-mediated solid phase extraction (SPE) for the enrichment and elution of preterm birth (PTB) biomarkers. Furthermore, this SPE module was integrated with microchip electrophoresis for combined enrichment and separation of multiple analytes, including a PTB peptide biomarker (P1). The team used a reversed-phase octyl methacrylate monolith that was polymerized as the SPE medium in polyethylene glycol diacrylate modified cyclic olefin copolymer microfluidic channels. Eluent for pH-mediated SPE of PTB biomarkers on the monolith was optimized using different pH values and ionic concentrations.

The scientists obtained a nearly 50-fold enrichment that was observed in single channel SPE devices for a low nanomolar solution of P1, with great elution time reproducibility. The monolith binding capacity was determined to be 400 pg (0.2 pmol). A mixture of a model peptide (FA) and a PTB biomarker (P1) was extracted, eluted, injected, and then separated by microchip electrophoresis in our integrated device with approximately 15-fold enrichment.

Adam T. Woolley, PhD, a chemistry professor and senior author of the study, said, “Among other benefits, the device is cheap, small and fast: once fully developed, it will help make detecting biomarkers a simple, automated task. Some peg the annual costs associated with preterm birth just in the USA at close to USD 30 billion, so one clear perk of such a screening tool, is economic. More significantly, there are a lot of preterm babies who don't survive: if we could get them to survive and thrive, it would be a huge gain to society.” The study was published on March 8, 2017, in the journal Electrophoresis.

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Automatic Hematology Analyzer
DH-800 Series

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more